Xenetic presents preclinical data on DNase I with CAR T cells in murine model

Written by Emily J. Thompson, Senior Investment Analyst

Source: Business Insider

Updated: Mar 13 2025

0mins

XBIO+7.59%

Should l Buy XBIO?

Source: Business Insider

Research Findings: Xenetic Biosciences presented preclinical data showing that co-administration of deoxyribonuclease I (DNase I) with CAR T cells significantly suppressed lung metastasis in a murine melanoma model, enhancing tumor control and survival compared to CAR T cell therapy alone.
Immune Response Improvement: The combination treatment led to increased infiltration of T and CAR T cells in tumors and reduced markers of T cell exhaustion, indicating that DNase I helps counteract the immunosuppressive environment of tumors.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy XBIO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on XBIO

About XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Xenetic Biosciences Reports FY 2025 Financial Results

Mar 13 2026seekingalpha

Net Loss Overview: For the year ended December 31, 2025, Xenetic Biosciences reported a net loss of approximately $2.7 million, reflecting the company's investment in its most promising scientific programs, indicating a commitment to future growth despite the losses.
Royalty Revenue Increase: Royalty revenue from the sublicense with Takeda Pharmaceuticals rose approximately 19% to $3.0 million, primarily due to royalty payments from certain countries, highlighting the company's potential for global market expansion.
R&D Expense Reduction: Research and development expenses decreased by approximately $0.2 million, or 7%, to $3.1 million, primarily due to a $0.7 million impairment charge in 2024 that did not recur in 2025, demonstrating improved cost control.
Historical Financial Data: Historical earnings data for Xenetic Biosciences and Seeking Alpha's Quant Rating provide investors with a comprehensive view of the company's financial health, aiding in the assessment of future investment opportunities.

Upstream Bio Shares Surge Nearly 20% on Positive Trial Results

Feb 11 2026stocktwits

Successful Clinical Trial: Upstream Bio's Phase 2 VALIANT trial results for Verekitug demonstrated significant efficacy, with a 56% reduction in annual asthma attacks at 100 mg and a 39% reduction at 400 mg, laying a solid foundation for the company's future market prospects.
Positive Patient Response: The study involving 478 participants supported Verekitug's safety profile, with most patients showing improved lung function, indicating the drug's strong potential in treating severe asthma.
Long-Term Study Expansion: More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment's durability, providing additional data support for the drug's market launch.
Positive Market Reaction: Following the encouraging trial results, Upstream Bio's shares surged nearly 20% in pre-market trading, reflecting investor confidence and expectations for the company's future growth.

What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?

Oct 08 2025TipRanks

Pharmaceutical Stock Movements: Several pharmaceutical stocks, including Xenetic Biosciences, Universe Pharmaceuticals, XTL Biopharmaceuticals, and Acurx Pharmaceuticals, saw significant pre-market gains despite no clear news or announcements explaining the rise.
Speculative Trading Influence: The surge in these stocks may be linked to speculative trading following a massive rally in Galecto shares, which spiked without news and then fell, indicating that retail traders are shifting their focus to other stocks for potential gains.

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Aug 12 2025NASDAQ.COM

Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).